A Phase 3 interventional study of E/C/F/TAF and B/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-05.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 295th largest by enrollment of the 638 interventional ones that give a count, is one of 36 that started in 2015, is one of 76 in phase 3, and was the 423rd registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 36 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is close to the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 610 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV-1) infected adults with end-stage renal disease (ESRD) on chronic hemodialysis (HD).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
Drug: E/C/F/TAF
At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
Drug: B/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablets administered orally once daily
Also known as: Genvoya®
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg FDC tablets administered orally once daily
Also known as: Biktarvy®
GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48
Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug or all AEs for participants still on E/C/F/TAF. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).
Time frame: First Dose Date Up to Week 48
GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 96
Treatment-emergent Adverse Events (TEAE) were defined as events that met 1 or both of the following criteria as any AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug for participants who did not participate in the BVY OL extension phase or the day prior to the date of the first B/F/TAF study drug dose for participants who participated in the BVY OL extension phase. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).
Time frame: First Dose Date Up to Week 96
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the FDA Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA Snapshot Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG), Cobicistat (COBI), Emtricitabine (FTC), and Tenofovir (TFV)
AUCtau is defined as area under the concentration versus time curve over the dosing interval (i.e., concentration of drug over time).
Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
PK Parameter: AUClast of EVG, COBI, FTC, Tenofovir Alafenamide (TAF), and TFV
AUClast is defined as the area under the concentration versus time curve from time zero to the last observable concentration.
Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
PK Parameter: Cmax of EVG, COBI, FTC, TAF, and TFV
Cmax is defined as the maximum concentration of drug.
Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
PK Parameter: Ctau of EVG, COBI, FTC, and TFV
Ctau is defined as the observed drug concentration at the end of the dosing interval. Ctau has been presented in lieu of Cmin (specified in the protocol) to align with other Gilead studies. This change has no impact on the PK analysis as Ctau and Cmin are equivalent for all analytes.
Time frame: 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose at or between Week 2 or Week 4
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Failure (M = F) Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 96
GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Excluded (M = E) Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
Time frame: Week 96
BVY OL Extension Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
Time frame: Week 48 of the BVY OL Extension Phase
GEN Phase: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 96
Time frame: Baseline; Week 96
BVY OL Extension Phase: Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48 of the BVY OL Extension Phase
GEN Phase: Change From Baseline in CD4 Percentage at Week 96
Time frame: Baseline; Week 96
BVY OL Extension Phase: Change From Baseline in CD4 Percentage at Week 48
Time frame: Baseline; Week 48 of the BVY OL Extension Phase
Participants were enrolled at study sites in Europe and the United States. The first participant was screened on 14 December 2015. The last study visit occurred on 15 October 2019.
| Milestone | E/C/F/TAF (GEN Phase) | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|---|
| Started | 55 | 0 |
| Completed | 39 | 0 |
| Not completed | 16 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Investigator's discretion | 4 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Withdrew consent | 5 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Milestone | E/C/F/TAF (GEN Phase) | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|---|
| Started | 0 | 10 |
| Completed | 0 | 10 |
| Not completed | 0 | 0 |
Treatment-emergent Adverse Events (TEAE) were defined as AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug or all AEs for participants still on E/C/F/TAF. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48 | 32.7 |
Treatment-emergent Adverse Events (TEAE) were defined as events that met 1 or both of the following criteria as any AEs with onset dates on or after the study drug start date and no later than 30 days after the permanent discontinuation of the E/C/F/TAF (GEN Phase) study drug for participants who did not participate in the BVY OL extension phase or the day prior to the date of the first B/F/TAF study drug dose for participants who participated in the BVY OL extension phase. It also includes the AEs that led to premature discontinuation of E/C/F/TAF study drug. Clinical events and clinically significant laboratory abnormalities were graded according to the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities. Adverse events were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening).
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 96 | 43.6 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the FDA Snapshot Algorithm | 87.3 (75.5 to 94.7) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Algorithm | 81.8 (69.1 to 90.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the FDA Snapshot Algorithm | 54.5 (40.6 to 68.0) |
AUCtau is defined as area under the concentration versus time curve over the dosing interval (i.e., concentration of drug over time).
| h*ng/mL | E/C/F/TAF (GEN Phase) |
|---|---|
| EVG | 14284.8 ± 7790.26 |
| COBI | 10179.5 ± 6009.28 |
| FTC | 62929.9 ± 30199.63 |
| TFV | 8715.0 ± 3432.16 |
AUClast is defined as the area under the concentration versus time curve from time zero to the last observable concentration.
| h*ng/mL | E/C/F/TAF (GEN Phase) |
|---|---|
| EVG | 12857.6 ± 7894.09 |
| COBI | 9558.7 ± 5963.16 |
| FTC | 59057.4 ± 31485.96 |
| TAF | 231.9 ± 123.46 |
| TFV | 7664.2 ± 3958.36 |
Cmax is defined as the maximum concentration of drug.
| ng/mL | E/C/F/TAF (GEN Phase) |
|---|---|
| EVG | 1258.5 ± 689.57 |
| COBI | 1370.4 ± 920.15 |
| FTC | 4875.0 ± 1981.03 |
| TAF | 246.3 ± 185.69 |
| TFV | 442.8 ± 181.03 |
Ctau is defined as the observed drug concentration at the end of the dosing interval. Ctau has been presented in lieu of Cmin (specified in the protocol) to align with other Gilead studies. This change has no impact on the PK analysis as Ctau and Cmin are equivalent for all analytes.
| ng/mL | E/C/F/TAF (GEN Phase) |
|---|---|
| EVG | 174.4 ± 104.36 |
| COBI | 28.9 ± 34.06 |
| FTC | 1277.3 ± 756.60 |
| TFV | 264.8 ± 193.98 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Failure (M = F) Approach | 61.8 (47.7 to 74.6) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 96 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
| percentage of participants | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 Using the Missing = Excluded (M = E) Approach | 100.0 (89.7 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 were analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
| percentage of participants | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|
| BVY OL Extension Phase: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach | 100.0 (69.2 to 100.0) |
| cells/µL | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 96 | -35 ± 218.3 |
| cells/µL | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|
| Baseline | 581 ± 146.8 |
| Change from Baseline at Week 48 | -104 ± 120.8 |
| percentage of CD4 cells | E/C/F/TAF (GEN Phase) |
|---|---|
| GEN Phase: Change From Baseline in CD4 Percentage at Week 96 | 2.8 ± 6.37 |
| percentage of CD4 cells | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|
| Baseline | 31.9 ± 7.37 |
| Change from Baseline at Week 48 | 1.7 ± 4.39 |
Collected over First dose date up to the last dose date [maximum: 114 Weeks (GEN Phase), 52 Weeks (BVY OL Extension Phase)] plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E/C/F/TAF (GEN Phase) | 3/55 (5.5%) | 36/55 (65.5%) | 41/55 (74.5%) |
| E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) | 0/10 (0%) | 3/10 (30%) | 10/10 (100%) |
| Event | E/C/F/TAF (GEN Phase) | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|---|
| PneumoniaInfections and infestations | 8/55 | 1/10 |
| HyperkalaemiaMetabolism and nutrition disorders | 6/55 | 1/10 |
| Acute myocardial infarctionCardiac disorders | 2/55 | 1/10 |
| Angina pectorisCardiac disorders | 1/55 | 1/10 |
| Cardiac failure congestiveCardiac disorders | 1/55 | 1/10 |
| Abdominal wall haematomaGastrointestinal disorders | 0/55 | 1/10 |
| Pneumonia respiratory syncytial viralInfections and infestations | 0/55 | 1/10 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/55 | 1/10 |
| Vascular access site haemorrhageInjury, poisoning and procedural complications | 0/55 | 1/10 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 1/55 | 1/10 |
| Event | E/C/F/TAF (GEN Phase) | E/C/F/TAF to B/F/TAF (BVY OL Extension Phase) |
|---|---|---|
| NauseaGastrointestinal disorders | 13/55 | 1/10 |
| HypertensionVascular disorders | 2/55 | 2/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/55 | 1/10 |
| HyperkalaemiaMetabolism and nutrition disorders | 8/55 | 1/10 |
| Oedema peripheralGeneral disorders | 6/55 | 0/10 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/55 | 0/10 |
| BradycardiaCardiac disorders | 0/55 | 1/10 |
| Ear painEar and labyrinth disorders | 1/55 | 1/10 |
| CataractEye disorders | 1/55 | 1/10 |
| DiplopiaEye disorders | 0/55 | 1/10 |
The GEN Safety Analysis Set included all participants who received at least 1 dose of GEN.
| Age, Continuous(years) | E/C/F/TAF (GEN Phase) |
|---|---|
| Mean | 48 ± 11.0 |
| Sex: Female, Male(Participants) | E/C/F/TAF (GEN Phase) |
|---|---|
| Female | 13 |
| Male | 42 |
| Ethnicity (NIH/OMB)(Participants) | E/C/F/TAF (GEN Phase) |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 47 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | E/C/F/TAF (GEN Phase) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 45 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | E/C/F/TAF (GEN Phase) |
|---|---|
| United States | 46 |
| France | 7 |
| Austria | 1 |
| Germany | 1 |
| HIV-1 RNA Category(Participants) | E/C/F/TAF (GEN Phase) |
|---|---|
| < 50 copies/mL | 54 |
| ≥ 50 copies/mL | 1 |
| Cluster Determinant 4+ (CD4+) Cell Count(cells/µL) | E/C/F/TAF (GEN Phase) |
|---|---|
| Mean | 545 ± 239.2 |
| CD4+ Cell Count Categories(Participants) | E/C/F/TAF (GEN Phase) |
|---|---|
| < 50 cells/µL | 0 |
| >= 50 to < 200 cells/µL | 0 |
| >= 200 to < 350 cells/µL | 12 |
| >= 350 to < 500 cells/µL | 14 |
| >= 500 cells/µL | 29 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2015 to primary completion in Sep 2017, 21 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 21 months is below that.
Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide · Bictegravir